-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Ultragenyx Pharmaceutical Sees FY22 Revenue $352M-$356M Vs $360.08M Est.; Sees FY23 Revenue $425M-$450M Vs $443.64M Est.

Benzinga · 01/06/2023 16:02

Financial Update

2022 Revenue (unaudited) and 2023 Revenue Guidance ($ in millions)

2022 2023
Preliminary Revenue Revenue Guidance
Crysvita in Ultragenyx Territories1 $257 - $258
Total Crysvita $277 - $279 $325 - $340
Dojolvi $55 - $56 $65 - $75
Total Product Revenue $352 - $356 $425 - $450